CILOSTAZOL ( DrugBank: Cilostazol )

---

3 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
51	全身性強皮症	1
70	広範脊柱管狭窄症	1
124	皮質下梗塞と白質脳症を伴う常染色体優性脳動脈症	1

51. 全身性強皮症

---

臨床試験数 : 523 /  薬物数 : 608 - (DrugBank : 156) / 標的遺伝子数 : 114 - 標的パスウェイ数 : 215

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2010-019977-14-IT (EUCTR)	04/11/2010	27/12/2010	Efficacy of Cilostazol for the treatment of Raynaud’s Phenomenon in patients affected by Systemic Sclerosis - ND	Efficacy of Cilostazol for the treatment of Raynaud’s Phenomenon in patients affected by Systemic Sclerosis - ND	Patients affected by Systemic Sclerosis with Raynaud’s Phenomenon MedDRA version: 9.1;Level: LLT;Classification code 10042953	Trade Name: PLETAL INN or Proposed INN: CILOSTAZOL	AZIENDA OSPEDALIERA UNIVERSITARIA SAN MARTINO GENOVA	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes			Italy

70. 広範脊柱管狭窄症

---

臨床試験数 : 96 /  薬物数 : 203 - (DrugBank : 60) / 標的遺伝子数 : 66 - 標的パスウェイ数 : 89

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	JPRN-UMIN000006588	2011/11/01	01/11/2011	Effect of antiplatelet agent on muscle cramps after surgery of lumbar spinal stenosis in patients with lumbar spinal canal stenosis and peripheral artery disease		Lumbar spinal canal stenosis	Continuous administration of cilostazol	Juntendo UniversityDepartment of Orthopaedic Surgery	NULL	Recruiting	Not applicable	Not applicable	Male and Female	30	Not applicable	Japan

124. 皮質下梗塞と白質脳症を伴う常染色体優性脳動脈症

---

臨床試験数 : 12 /  薬物数 : 14 - (DrugBank : 5) / 標的遺伝子数 : 6 - 標的パスウェイ数 : 23

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04753970 (ClinicalTrials.gov)	February 9, 2021	9/2/2021	Retina is a Marker for Cerebrovascular Heath	Retinal Vasoreactivity is a Marker for Cerebral Small Vessel Disease Progression	Cerebral Small Vessel Diseases;Cerebral Autosomal Dominant Arteriopathy With Subcortical Infarcts and Leukoencephalopathy;Cerebral Microbleeding;Sporadic White Matter Disease	Drug: Cilostazol	Mayo Clinic	NULL	Recruiting	18 Years	N/A	All	40	Phase 1/Phase 2	United States